Loblaw, a leading grocery retailer, reported increased profits in the second quarter, attributing the growth to successful strategies at its discount chains, No Frills and Maxi. The company highlighted robust sales in its pharmacy division, citing the impact of generic GLP-1 weight loss drugs as a key driver.
Based in Brampton, Ont., Loblaw disclosed its financial performance for the three-month period ending June 20. The company revealed a revenue exceeding $15.3 billion, marking a four percent uptick from the previous quarter. Profit attributable to common shareholders surged by five percent to $751 million.
Loblaw noted a 1.6 percent rise in same-store sales for its core retail food business, while its drug retail unit, which includes Shoppers Drug Mart, saw a substantial 4.6 percent growth in same-store sales. This increase was primarily fueled by a 7.5 percent uptick in pharmacy and health-care services.
During a conference call with market analysts, Chief Financial Officer Richard Dufresne emphasized the strong performance of the pharmacy segment, particularly driven by the growth in specialty prescription sales and the emergence of generic GLP-1 drugs. Dufresne highlighted the positive outlook, expecting increased revenue and profitability despite lower generic drug pricing.
The company’s executives reported a significant increase in the sales of GLP-1 drugs, reaching 40 percent year-to-date, reflecting a trend observed since the previous quarter report in May.
CEO Per Bank shared insights on consumer behavior, noting a shift towards purchasing frozen vegetables over fresh produce due to inflationary pressures. The company observed a notable increase in frozen vegetable sales at its discount stores, No Frills and Maxi, as customers seek cost-effective options amidst rising food prices.
Loblaw remains optimistic about its positioning in the market, with a focus on providing value to customers amidst ongoing food price inflation. The company continues to excel in the hard discount sector and outperform industry peers in conventional retail.
Despite economic fluctuations, Loblaw’s performance remains steady, with its Toronto-listed shares showing minimal movement on Thursday. Year-to-date, the stock has demonstrated a positive trend, gaining approximately six percent.